Literature DB >> 22791308

Enhancement of antitumor activity of low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules in hepatoma 22 tumor-bearing mice.

Zhiyun Cao1, Lianming Liao, Xuzheng Chen, Lan Lan, Haixia Hu, Zhizhen Liu, Liwu Chen, Suping Huang, Jian Du.   

Abstract

OBJECTIVE: The adverse effects of 5-fluorouracil (5-FU) are well recognized. Fuzheng-Yiliu granule (FYG) is capable of enhancing the immune function and suppressing tumor growth. In the present study, the authors evaluated if FYG could synergize with low-dose 5-FU in inhibiting tumor growth.
METHODS: Hepatoma 22 (H22) tumor-bearing mice were treated with FYG (18 g/kg, ig), 5-FU (10 mg/kg, ip), or 5-FU plus FYG for 5 days. The relative tumor proliferation rates, tumor weight and apoptosis of tumor tissue were measured. White blood cell (WBC) and lymphocyte (LY) were counted. Interleukin-2 (IL-2) and tumor necrosis factor (TNF-a) in the serum were measured.
RESULTS: FYG alone had antitumor effect. Combination of 5-FU and FYG produced a more potent antitumor effect and caused more marked apoptosis in tumor tissue (compared with vehicle, P < 0.01; compared with 5-FU or FYG, P < 0.05). Mice treated with 5-FU plus FYG had higher thymus index (P < 0.05) compared with the vehicle group. The numbers of both WBC and LY were decreased by 5-FU (compared with vehicle, P < 0.01), which was significantly reversed after FYG was administered (5-FU + FYG vs 5-FU, P < 0.01 and P < 0.05). Mice receiving FYG alone or FYG plus 5-FU had higher serum levels of TNF-a (P <0.01) compared with the vehicle.
CONCLUSIONS: Traditional Chinese medical herbs capable of strengthening the body's vital energy have great potential to be used as an adjuvant therapy for cancer patients who cannot tolerate the adverse effects of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791308     DOI: 10.1177/1534735412450514

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  8 in total

1.  Combination of calcineurin B subunit (CnB) and 5-fluorouracil reverses 5-fluorouracil-induced immunosuppressive effect and enhances the antitumor activity in hepatocellular carcinoma.

Authors:  Wenlong Zhang; Youxiu Zhong; Hongfei Cui; Liya Wang; Rui Yang; Zhenyi Su; Benqiong Xiang; Qun Wei
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

2.  Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response.

Authors:  Menghua Chen; Brian H May; Iris W Zhou; Charlie C L Xue; Anthony L Zhang
Journal:  Integr Cancer Ther       Date:  2015-08-06       Impact factor: 3.279

3.  NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer.

Authors:  Justin Maykel; Jian Hua Liu; Hanchen Li; Leonard D Shultz; Dale L Greiner; JeanMarie Houghton
Journal:  Dig Dis Sci       Date:  2014-05-06       Impact factor: 3.199

4.  Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation.

Authors:  Zhizhen Liu; Lianming Liao; Zhiyun Cao; Xuzheng Chen; Jian Du
Journal:  Oncol Rep       Date:  2016-12-28       Impact factor: 3.906

Review 5.  Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity.

Authors:  Wentao Jia; Lina Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-11       Impact factor: 2.629

6.  Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.

Authors:  Xunan Li; Xiang Wang; Nian Liu; Qiuyu Wang; Jing Hu
Journal:  Molecules       Date:  2022-03-24       Impact factor: 4.411

Review 7.  Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective.

Authors:  Hor-Yue Tan; Serban San-Marina; Ning Wang; Ming Hong; Sha Li; Lei Li; Fan Cheung; Xiao-Yan Wen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-28       Impact factor: 2.629

8.  Combination of traditional Chinese medicine and epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Xinbing Sui; Mingming Zhang; Xuemeng Han; Ruonan Zhang; Liuxi Chen; Ying Liu; Yu Xiang; Tian Xie
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.